Head-to-head evidence
PLX-61639 vs PRT3789
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SMARCA2 · full Non-Small Cell Lung Cancer pipeline
PLX-61639
Developed by Plexium, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
PRT3789
Developed by Prelude Therapeutics
NCT05639751 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PLX-61639's landscape · PRT3789's landscape